Enfusion, Inc. (NYSE:ENFN – Get Free Report) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a decline of 22.4% from the October 15th total of 1,520,000 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average daily trading volume, of 381,300 shares, the short-interest ratio is currently 3.1 days.
Enfusion Price Performance
Shares of NYSE ENFN opened at $9.88 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 248.06, a price-to-earnings-growth ratio of 3.55 and a beta of 0.93. The business has a 50-day moving average of $8.93 and a two-hundred day moving average of $8.85. Enfusion has a 1 year low of $7.52 and a 1 year high of $10.45.
Institutional Trading of Enfusion
Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new stake in Enfusion during the 1st quarter worth about $44,000. RiverPark Advisors LLC purchased a new stake in Enfusion during the 2nd quarter worth about $68,000. Arizona State Retirement System purchased a new stake in Enfusion during the 2nd quarter worth about $86,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Enfusion in the 1st quarter valued at about $102,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Enfusion in the 1st quarter valued at about $109,000. 81.05% of the stock is owned by hedge funds and other institutional investors.
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
- Five stocks we like better than Enfusion
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Why Invest in High-Yield Dividend Stocks?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- 3 Warren Buffett Stocks to Buy Now
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.